What Are Omega-3 Fatty Acids?
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 fatty acids found mainly in fatty marine fish (salmon, mackerel, sardines) and algae oil. The body can produce them in limited amounts from plant-based ALA (e.g., flaxseed oil), but the conversion rate is only ~5–8% for EPA and less than 0.5–5% for DHA. Direct supplementation therefore makes sense for vegans and those who eat little or no fish.
Omega-3 is one of the rare supplements where the evidence base is genuinely strong — for specific applications.
What Do the Studies Show?
Clearly established
Triglyceride reduction: One of the best-documented effects of any supplement. Meta-analyses consistently show a 25–30% reduction in triglycerides at doses of 2–4 g EPA+DHA per day. Even at lower doses (1 g/day) moderate effects are reproducible.
Cardiovascular benefit in high-risk patients: The REDUCE-IT trial (Bhatt 2019, n=8,179) in patients with elevated triglycerides on statin therapy: high-dose EPA (4 g/day as Vascepa/icosapentaenoic acid ethyl ester) reduced major cardiovascular events by 25% vs. placebo (HR 0.75; 95% CI 0.68–0.83). A dramatic result for a supplement.
Brain and visual function: EFSA-approved claims for DHA, supported by robust human data (250 mg/day sufficient for these claims).
Primary prevention — nuanced picture: The VITAL trial (Manson 2019, n=25,871) found no significant overall effect of 1 g/day in primary prevention, but a 28% reduction in myocardial infarctions (HR 0.72; 95% CI 0.59–0.90).
Less certain
REDUCE-IT vs. STRENGTH: The discrepancy between these trials has not been fully explained. STRENGTH (Nicholls 2020, n=13,078) with an EPA+DHA combination (4 g/day) found no significant advantage — possibly due to different control oils or EPA-vs.-DHA differences.
Atrial fibrillation risk is a real trade-off: A 2026 meta-analysis of DHA/EPA, cardiovascular outcomes, and atrial fibrillation (PMID 42144851) reinforces why omega-3 must be read carefully: the ingredient remains strong for triglycerides and selected cardiovascular endpoints, but the literature increasingly forces a balancing of benefit against possible atrial fibrillation risk. For high-risk patients the overall equation may still be favorable — but the evidence no longer supports simplistic “everyone should take as much fish oil as possible” messaging.
Healthy individuals without risk factors: In people with normal triglycerides and low cardiovascular risk, the measurable additional benefit from supplementation is smaller.
Longevity / lifespan extension in healthy people: Not directly established. Anti-inflammatory effects are well documented, but whether they translate into reduced mortality is unclear.
What to Look for in Quality
The market is noisy. These quality markers matter:
| Feature | What it means |
|---|---|
| EPA+DHA content per capsule | Many cheap products contain only 300 mg EPA+DHA per 1,000 mg capsule — the rest is other fats |
| TOTOX value | Measure of oxidation; should be below 26 — rancid oil is counterproductive |
| Fatty acid form | Triglyceride form (TG) is better absorbed than ethyl ester form (EE) |
| IFOS certification | Independent quality testing for fish oil supplements |
A 2026 RCT (Loukil, n=72) shows that krill oil raises plasma EPA and DHA approximately 1.5× more than fish oil at the same omega-3 dose — due to the superior bioavailability of the phospholipid form. Relevant for product choice when bioavailability is a concern.
Vegan Alternatives
Algae oil delivers DHA directly at the source (fish accumulate omega-3 through algae consumption). EPA content in algae oil is lower in many products than in fish oil — check the exact EPA+DHA composition on the label.
Dosage
- General health / triglycerides: 1–2 g EPA+DHA/day
- High-risk cardiovascular patients (under medical supervision): 2–4 g EPA/day (used in clinical trials)
- Pregnancy / breastfeeding: At least 200 mg DHA/day per EFSA
Omega-3 is generally well tolerated. At higher doses, fishy aftertaste can occur — enteric-coated capsules help. Blood-thinning effects at very high doses (>3 g/day) should be discussed with a doctor before surgery.
Limitations
- The REDUCE-IT controversy (mineral oil placebo vs. genuine blinding) has not been scientifically resolved
- Many studies have short durations under 2 years; long-term mortality effects are difficult to measure
- Quality differences between products are substantial — results from clinical trials with highly purified study preparations don’t automatically apply to inexpensive supermarket products
EFSA Status
EFSA has approved several health claims for omega-3 fatty acids — among the few supplements with EU-recognised claims:
- EPA + DHA contribute to normal cardiac function (250 mg/day)
- DHA contributes to maintenance of normal brain function (250 mg/day)
- DHA contributes to maintenance of normal vision (250 mg/day)
- DHA maternal supplementation contributes to normal brain and eye development of the foetus and breast-fed infant
Summary
Omega-3 (EPA + DHA) is one of the relatively few supplements with strong evidence for specific applications. For triglycerides and cardiovascular risk, the evidence is compelling. For healthy individuals without risk factors, the additional measurable benefit from supplementation is smaller — but the safety profile at 1–2 g/day is excellent.